Skip to main navigation Skip to search Skip to main content

TALLY - A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Project: Research

Project Details

StatusFinished
Effective start/end date12/10/18 → 02/12/23

Funding

  • Biogen MA Incorporated: $23,453.60